Seres therapeutics, inc. (MCRB)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenue:
Collaboration revenue - related party

27,188

26,917

32,100

21,766

-

-

-

Grant revenue

1,102

1,350

-

-

-

-

-

Collaboration revenue

6,215

-

-

-

-

-

-

Total revenue

34,505

28,267

32,100

21,766

-

-

-

Operating expenses:
Research and development expenses

80,141

95,955

89,455

81,989

38,095

10,718

4,805

General and administrative expenses

24,748

32,596

34,040

32,616

16,761

4,364

1,247

Restructuring expenses

1,492

0

0

-

-

-

-

Total operating expenses

106,381

128,551

123,495

114,605

54,856

15,082

6,052

Loss from operations

-71,876

-100,284

-91,395

-92,839

-54,856

-15,082

-6,052

Other income (expense):
Interest income

1,033

1,172

1,590

-

-

-

-

Interest expense

502

-

-

-

-

-

-

Interest income (expense), net

-

-

-

1,260

-

-

-

Interest expense

-

-

-

-

-

209

42

Interest income (expense), net

-

-

-

-

83

-

-

Other income

1,066

170

425

-

-

-

-

Revaluation of preferred stock warrant liability

-

-

-

-

-7

-1,418

-8

Total other income (expense), net

1,597

1,342

2,015

1,260

76

-1,627

-50

Net loss

-70,279

-98,942

-89,380

-91,579

-54,780

-16,709

-6,102

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

1,291

875

Net loss attributable to common stockholders

-

-

-

-

-

-18,000

-6,977

Net loss per share attributable to common stockholders, basic and diluted

-1.24

-2.43

-2.21

-2.30

-2.33

-2.67

-1.09

Weighted average common shares outstanding, basic and diluted

56,649

40,743

40,449

39,846

23,532

6,748

6,394

Net loss

-70,279

-98,942

-89,380

-

-

-

-

Other comprehensive loss:
Unrealized loss on investments, net of tax of $0

-

146

3

-179

30

-

-

Total other comprehensive loss

-

146

3

-179

-

-

-

Total other comprehensive income

-

-

-

-

30

-

-

Comprehensive loss

-70,279

-98,796

-89,377

-91,758

-54,750

-18,000

-6,977